Pursuant to Regulation 32 of SEBI (LODR) Regulations 2015 and SEBI circular dated December 24, 2019 regarding the submission of a Statment of Deviation or Variation for the use of proceeds, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Valencia Nutrition filed a routine SEBI Regulation 32 compliance statement confirming no deviation or variation in the use of proceeds from its prior fund raises. The Rights Issue of equity shares (raised April 23, 2024, net proceeds ~Rs. 20.43 Cr) has been fully utilised across working capital (~Rs. 12.35 Cr), adjustment of promoter unsecured loans (~Rs. 3 Cr), and general corporate purposes (~Rs. 5.08 Cr), with a statutory auditor certificate confirming full deployment. For the Preferential Issue (Rs. 12.07 Cr) and Convertible Warrants (Rs. 20 Cr, of which 25% i.e. Rs. 5 Cr received) raised on January 28, 2025, the company has utilised Rs. 17.02 Cr out of Rs. 17.07 Cr allocated towards setting up a manufacturing unit, new product development and marketing, the online platform, and general corporate purposes. The Audit Committee reviewed and approved the Nil deviation statement.
This is a clean, positive compliance disclosure showing disciplined fund usage with no diversions, which reduces execution risk for shareholders. As a routine regulatory filing with no new corporate action, the direct stock price impact is limited but reinforces management credibility on stated use-of-proceeds.